Literature DB >> 16282217

Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.

Joseph T King1, Joel Tsevat, Judith R Lave, Mark S Roberts.   

Abstract

BACKGROUND: Health-state preferences can be combined with willingness-to-pay (WTP) data to calculate WTP per quality-adjusted life year (QALY). The WTP/QALY ratios provide insight into societal valuations of expenditures for medical interventions.
METHODS: The authors measured preferences for current health in 3 patient populations (N = 391) using standard gamble, time trade-off, visual analog scale, and WTP, then they calculated WTP/QALY ratios. The ratios were compared with several proposed cost/QALY cost-effectiveness ratio thresholds, the value-of-life literature, and with WTP/QALY ratios derived from published preference research.
RESULTS: Mean WTP/QALY ratios ranged from 12,500 to 32,200 US dollars (2003 US dollars). All values were below most published cost-effectiveness ratio thresholds, below the ratio from a prototypic medical treatment covered by Medicare (i.e., renal dialysis), and below ratios from the value-of-life literature. The WTP/QALY ratios were similar to those calculated from published preference data for patients with symptomatic meno-pause, dentofacial deformities, asthma, or dermatologic disorders.
CONCLUSIONS: WTP/QALY ratios calculated using preference data collected from diverse populations are lower than most proposed thresholds for determining what is "cost-effective." Current proposed cost-effectiveness ratio thresholds may overestimate the willingness of society to pay for medical interventions.

Entities:  

Mesh:

Year:  2005        PMID: 16282217     DOI: 10.1177/0272989X05282640

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  60 in total

1.  The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries.

Authors:  Raymond Oppong; Billingsley Kaambwa; Jacqueline Nuttall; Kerenza Hood; Richard D Smith; Joanna Coast
Journal:  Eur J Health Econ       Date:  2011-11-05

2.  A game-theoretic framework for estimating a health purchaser's willingness-to-pay for health and for expansion.

Authors:  Reza Yaesoubi; Stephen D Roberts
Journal:  Health Care Manag Sci       Date:  2010-08-12

3.  Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Rebecca I Hartman; Mukesh G Harisinghani; Adam S Feldman; Peter R Mueller; G Scott Gazelle
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

4.  The value of a QALY: individual willingness to pay for health gains under risk.

Authors:  Ana Bobinac; Job van Exel; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

5.  The Cost-Effectiveness of Surgical Fixation of Distal Radial Fractures: A Computer Model-Based Evaluation of Three Operative Modalities.

Authors:  Prashant V Rajan; Rameez A Qudsi; George S M Dyer; Elena Losina
Journal:  J Bone Joint Surg Am       Date:  2018-02-07       Impact factor: 5.284

6.  Mitigating hypothetical bias in willingness to pay studies: post-estimation uncertainty and anchoring on irrelevant information.

Authors:  Ana Bobinac
Journal:  Eur J Health Econ       Date:  2018-05-23

7.  Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Peter R Mueller; Chin Hur; G Scott Gazelle
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

8.  Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Authors:  Tracy A Lieu; G Thomas Ray; Ismael R Ortega-Sanchez; Ken Kleinman; Donna Rusinak; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.

Authors:  Pamela P Pei; Milton C Weinstein; X Cynthia Li; Michael D Hughes; A David Paltiel; Taige Hou; Robert A Parker; Melanie R Gaynes; Paul E Sax; Kenneth A Freedberg; Bruce R Schackman; Rochelle P Walensky
Journal:  HIV Clin Trials       Date:  2015-12-11

10.  Preferences for health outcomes associated with Group A Streptococcal disease and vaccination.

Authors:  Grace M Lee; Joshua A Salomon; Charlene Gay; James K Hammitt
Journal:  Health Qual Life Outcomes       Date:  2010-03-12       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.